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ABSTRACT 
INTRODUCTION: Acute Interstitial Pneumonia (AIP) is a rare form of interstitial lung 
disease, with a non-specific clinical and radiologic presentation, which frequently 
mimics acute respiratory distress syndrome (ARDS). The diagnosis is one of exclusion. 
No proven effective treatment exists and the use of glucocorticoids remains 
controversial. Venovenous Extracorporeal membrane oxygenation (VV-ECMO), 
referring to an extracorporeal circuit that directly oxygenates and removes carbon 
dioxide from the blood, may be considered in refractory cases of severe acute 
respiratory failure, as a bridge to a diagnosis, treatment and eventually recovery. We 
present 3 cases of patients with AIP supported with VV-ECMO.  
METHODS: One male and two female patients are described. After excluding known 
causes of ARDS, AIP was diagnosed after a lung biopsy and immunosuppressive 
treatment was initiated. 
RESULTS: Despite the usual care for severe acute respiratory failure, patients were 
not improving and VV-ECMO was started and used as a bridge to diagnosis. Two 
patients survived (duration of ECMO support: 15 days in both patients) and one died as 
a result of lung biopsy complication (ECMO support: 73 days). 
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CONCLUSIONS: Our report highlights the potential role of VV-ECMO in the diagnosis 
and management of refractory severe acute respiratory failure associated to AIP. 
KEYWORDS: Acute Interstitial Pneumonia; Extracorporeal Membrane Oxygenation, 
Acute Respiratory Distress Syndrome. 
INTRODUCTION 
Acute Interstitial Pneumonia (AIP) is a rare form of interstitial lung disease of 
unknown etiology, first described in 1965 by Hamman and Rich.1 AIP has a poor 
prognosis with a mortality >50 % in the first two months after the onset of the disease.2 
It mostly occurs in previously healthy individuals without pre-existing lung disease, has 
no gender predominance nor association with smoke and can manifest at any age with 
a mean age of occurrence of 50 years.3 AIP has an acute onset and is generally 
preceded by upper respiratory infection symptoms or by a flu-like disease, followed by 
rapidly progressive hypoxemic respiratory failure frequently requiring invasive 
mechanical ventilatory support.4   
The clinical and radiologic presentation of AIP is non-specific and frequently 
mimics acute respiratory distress syndrome.5 There are no specific laboratory findings 
but patients may present with nonspecific leukocytosis with neutrophilia.6 Chest x-ray 
display bilateral, diffuse air-space opacities sparing the costophrenic angles.3 High 
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resolution computed tomography reveals bilateral ground glass opacities, frequently 
with consolidation of the dependent lung regions.7 Bronchoalveolar lavage (BAL) 
shows increased total cell number including red blood cells, neutrophils and 
occasionally lymphocytes; atypical reactive pneumocytes as well as hyaline membrane 
fragments can also be seen3. 
The diagnosis of AIP requires the presence of a diffuse alveolar damage (DAD) 
histologic pattern in lung biopsy, which is also frequently observed in patients with 
ARDS. Therefore, known causes of DAD such as infection, acute exacerbation of 
idiopathic pulmonary fibrosis, acute hypersensitivity pneumonitis, connective tissue 
disorders, drug toxicity, aspiration, inhalants toxins and pancreatitis need to be 
excluded in order to establish a diagnosis of AIP6. The DAD characteristic histologic 
pattern in the initial phases of the disease consists of edema, acute interstitial 
inflammation and hyaline membrane formation, with absorption of these membranes as 
the progression of disease occurs, as well as migration of fibroblasts to the alveolar 
septa. In more advanced phases, an interstitial thickening caused by fibroblasts can be 
seen as a loose organizing fibrosis.3 
There is no proven effective treatment for AIP.3 In patients requiring invasive 
mechanical ventilation a lung-protective approach consisting in tidal volumes of 6 ml/kg 
5 
 
predicted body weight and a plateau pressure below 30 cmH2O is recommended in 
order to minimize ventilator-induced lung injury, as in ARDS.8 Regarding the 
pharmacological treatment, the use of glucocorticoids remains controversial.3 The use 
of high dose glucocorticoids in the treatment of AIP is based on a lower mortality 
described in lupus pneumonitis 9 and ARDS6, with such therapy, claiming that the same 
can occur with AIP. However, some authors have not found benefits of glucocorticoid 
therapy neither for AIP 4 nor for ARDS.10  
 Extracorporeal membrane oxygenation (ECMO), referring to an extracorporeal 
circuit that directly oxygenates and removes carbon dioxide from the blood, may be 
considered in refractory severe acute respiratory failure when positive-pressure 
ventilation alone is insufficient to maintain adequate gas exchange, or when adherence 
to lung-protective ventilation strategies, neuromuscular block, prone position and 
conservative strategy of fluid management results in unacceptable levels of hypoxemia, 
hypercapnia and acidemia.11 In most cases of ECMO for severe acute respiratory 
failure, venovenous (VV) ECMO is utilized, in which blood is withdrawn from and 
returned to a central vein.12 Recently, there has been increasing interest in ECMO as a 
result of advances in extracorporeal technology, with more efficient oxygenators and 
lower rates of complications, along with several reports of improved survival with 
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ECMO for severe ARDS.13 In the Conventional ventilation or ECMO for Severe Adult 
Respiratory failure (CESAR) trial, transferring of adult patients with severe but 
potentially reversible respiratory failure to an ECMO Center significantly improved 
survival without severe disability at 6 months, when compared with the conventional 
management group.14  
Centro Hospitalar São João is a 1100-bed tertiary university hospital and the 
sole ECMO referral center of the north of Portugal, a region with approximately 4 
million inhabitants. It has a case volume of 40 to 50 patients per year, being an 
Extracorporeal Life Support Organisation (ELSO) member (Center 227). 
In the present study we describe 3 cases of refractory severe acute respiratory 
failure of unclear etiology rescued with VV-ECMO.  
METHODS 
Case 1 
A 27-years-old woman with a past medical history of obesity and on oral 
contraceptives began with odynophagia and fever (Table 1), that persisted despite 
antibiotic therapy. Five days later purulent cough developed and levofloxacin was 
started. She evolved with prostration, asthenia, worsening dyspnea and she went to 
the emergency department of a secondary hospital. On admission she had a 
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respiratory rate of 32 breaths pm, peripheral saturation of 56% on air, crackles in the 
right hemithorax, blood pressure 110/60 mmHg, heartbeat of 110 pm, Glasgow Score 
of 15 and a tympanic temperature of 39.5ºC. Arterial blood gas analysis on air showed 
severe respiratory insufficiency (PO2 17 mmHg, pH 7.50, CO2 32mmHg, HCO3 
26mEq/L). Lactate was 2.3mmol/L. Blood tests revealed an elevated C reactive protein 
(128.7 mg/dL), normal white blood count and no renal, hepatic and hematological 
dysfunction. Chest X-ray showed consolidation of the right pulmonary base. A 
provisional diagnosis of severe community-acquired pneumonia (CAP) was made, 
treatment started with meropenem, oseltamivir, fluids, invasive mechanical ventilation 
and transfer to our hospital for ICU care. Reassessment on mechanical ventilation 
revealed severe acute respiratory insufficiency (PO2 46 mmHg with a PEEP of 15 and 
FIO2 of 100%, with normal PCO2, HCO3 and lactate values) and hemodynamic stability. 
Chest X-ray showed consolidation of the right and of the inferior two thirds of the left 
lungs. (Figure 1) Neuromuscular blockade was initiated and antibiotics changed to 
piperacillin/tazobactam, azithromycin plus oseltamivir. Cultural and non-cultural 
microbiological results from BAL were negative, including for virus and atypical agents. 
Oseltamivir was stopped and the antibiotics were kept for 8 and 5 days, respectively. 
The clinical status continued to worse over the next days and a chest CT scan was 
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performed, showing diffuse bilateral ground glass pattern and inferior lobar 
consolidation. Refractory hypoxemia with aggressive ventilation (plateau pressure 
(Pplat) 30 cm H2O, PEEP 15, FIO2 100%) was still needed by day 6 of mechanical 
ventilation (Table 2), when ECMO was initiated (23Fr aspiration cannula in the femoral 
vein and a 17Fr arterialize cannula in internal jugular vein) (Table 3). A surgical lung 
biopsy was performed on the 2nd day of ECMO and a diffuse alveolar damage pattern 
in organizing phase was observed (Figure 2), with negative microbiological and cancer 
search (Table 4).  Immunosuppressive therapy was started with methylprednisolone 
(1g a day during 5 days and then 2mg/kg/d) and intravenous cyclophosphamide 
(2g/month), on the 3rd day of ECMO. Right hemopneumothorax developed as a 
consequence of the lung biopsy and was managed with chest tubes (two) and 
hematologic support according with the needs. Minor vaginal bleeding responded to 
estradiol. After 15 days of progressive improvement on ECMO, decannulation was 
safely performed and the patient weaned from mechanical ventilation in the next 5 
days. She was transferred to a level II-ICU in the 28th inpatient day, where she stayed 
for 11 days, recovering from critical illness myopathy and residual respiratory failure, 
treating a recurrent pneumothorax and Proteus mirabilis acute pyelonephritis (5 days 
meropenem). Later she was transferred to the pulmonology ward where respiratory 
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failure fully resolved, completing 51 days of global hospital stay. Currently she remains 
without respiratory symptoms and without any immunosuppressive therapy, after a two 
years azathioprine course.  
Case 2 
A 59-year-old man with a past medical history of ulcerative colitis managed with 
mesalazine and prednisolone, came to our emergency department with a 3-day history 
of progressive worsening dyspnea, asthenia and dry cough. On admission, he had a 
respiratory rate of 32 breath pm, peripheral saturation of 70% on air and diminished 
breath sounds and crackles in both lung bases on auscultation. He was 
hemodynamically stable, with a Glasgow Score of 15 and a tympanic temperature of 
38.4ºC. The arterial blood analysis on air showed a severe type I respiratory failure 
(PO2 35mmmHg). Blood tests revealed hemoglobin 12g/dL, leucopenia (WBC 
3000/mm3), elevated C reactive protein (91mg/dL) and no renal, hepatic or hematologic 
dysfunction. Chest X-ray showed heterogeneous infiltrates in both inferior halves of the 
lungs. (Figure 3) A provisional diagnosis of CAP was made and treatment with 
ceftriaxone, azithromycin and oseltamivir started, together with ICU admission for non-
invasive mechanical ventilation support. Due to negative non-cultural microbiological 
results and confirmation of recent exposure to prednisolone, antibiotics were changed 
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to piperacillin/tazobactam plus azithromycin. Cultural results (endotracheal aspirate 
and blood cultures) were also negative. The patient evolved with worsening respiratory 
failure despite invasive mechanical ventilation, curarization, prone positioning, negative 
fluid balance and an attempt of protective ventilator strategy with permissive 
hypercapnia. On the 5th ICU day, ECMO was started (19Fr cannula in the right internal 
jugular vein and 25Fr cannula in the right femoral vein). A flexible bronchoscopy 
showed no signs of typical and atypical infections (bacteriologic, acid-fast, mycological, 
virological study as well as PCR for Aspergillus, Chlamydia, CMV, Legionella, Influenza 
A and Coxiella were all negative) or of lung cancer. The bronchalveolar lavage fluid 
had a neutrophil predominance with mild eosinophilia (11%) and no lymphocytosis. A 
right pneumothorax subsequent to bronchoscopy led to pleural drain insertion. A CT 
scan performed on the 3rd ECMO day showed right pneumothorax with well-placed 
drain, minor bilateral pleural effusion, inferior and superior lobes consolidation with a 
ground glass pattern in the remaining parenchyma. A surgical lung biopsy was 
performed on the 9th ECMO day and it showed pulmonary parenchyma with diffuse 
alveolar damage pattern in organizing phase (Figure 4), with negative microbiological 
and cancer search. Methylprednisolone was started (2mg/kg/d) and the patient evolved 
favorably in the next days, being successfully decannulated on the 15th ECMO day. He 
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stayed for more 16 days in the ICU due to difficult mechanical ventilation weaning 
associated with a bronchopleural fistula (post bronchoscopy and biopsy) and myopathy 
secondary to corticosteroids and critical illness. He was transferred to a level II-ICU on 
the 37th inpatient day, where he stayed for 22 days and was transferred to an internal 
medicine ward on the 59th inpatient day, and 7 days later to a rehabilitation center. 
Currently he remains on hospital follow-up as a rheumatology and gastroenterology 
outpatient, without respiratory symptoms.  
Case 3  
A 56-year-old woman with a past medical history of unilateral renal agenesis 
and major depressive disorder treated with quetiapine, sertraline, clomipramine and 
lorazepam, went to the emergency department with a 3-day history of fever, dry cough, 
dizziness and respiratory difficulty. On admission she had a respiratory rate of 36 
breaths pm, peripheral saturation of 81% with a nonrebreathing face mask with 
reservoir (FIO2 85%), severe dyspnea, crackles on the right hemithorax, hemodynamic 
stability and a Glasgow Score of 15. The arterial blood gas showed severe hypoxemia 
(pH 7.41, PCO2 41mmHg, PO2 48mmHg, HCO3 26.0mEq/L). Lactate was 1.1 mmol/L. 
Blood tests revealed normal white blood count (with neutrophilia), elevated C reactive 
protein (350mg/dL), myoglobin and D-dimers, with no renal, hepatic and hematological 
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dysfunction. Chest X-ray showed diffuse bilateral infiltration. A provisional diagnosis of 
severe CAP was made and ceftriaxone, hydrocortisone, enoxaparin and invasive 
mechanical ventilation initiated. During the ICU stay azithromycin was added to 
ceftriaxone. Blood cultures and urinary antigens for Pneumococcus and Legionella 
were negative (no influenza virus testing was made). She evolved in the next days with 
persistent hypoxemia refractory to prone position, curarization, recruitment maneuvers, 
negative fluid balance and aggressive ventilation (tidal volume 470cc, PEEP 16, F IO2 
100% Inspiration: Expiration 1:1, Pplat 30 cmH20). Shock and persistent inflammatory 
syndrome was also present, despite antibiotics switch to piperacillin plus tazobactam 
(initiated after a thoracic angio-CT scan, a flexible bronchoscopy with bronchalveolar 
lavage and new blood cultures). ECMO was started in loco on the 7th ICU day (25Fr 
cannula in the femoral vein and a 19Fr cannula in internal jugular vein), followed by 
transport to our hospital (Figure 5). Rest ventilation was initiated and antibiotic 
sustained for a total of 8 days, according to negative microbiological results in the 
reference hospital. She persisted on ECMO with multiorgan dysfunction and with an 
increasing inflammatory syndrome. Vesicles and ulcers develop on the oral mucosa 
and acyclovir initiated after a blood positive molecular result to herpes simplex type 1 
infection. The patient showed no signs of improvement and a thoracic and abdominal 
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CT scan showed extended areas of consolidation and ground glass pattern more 
exuberant in the inferior pulmonary lobes. A surgical lung biopsy (access by 
minithoracotomy, with chest tube insertion under direct visualization) was held, 
revealing a morphologic picture of diffuse alveolar damage in organizing phase (Figure 
6), without evidence of infection or cancer. Methylprednisolone (1g/day in the first 5 
days, then 2 mg/kg/day) was started. The patient developed signs of intubation 
associated pulmonary infection and imipenem plus vancomycin were initiated. An 
Acinetobacter baumannii only susceptible to imipenem and aminoglycosides was 
isolated in a bronchial lavage, and combined therapy with meropenem plus sulbactam 
initiated. A bronchopleural fistula with a persistent pneumothorax developed as a 
consequence of the lung biopsy, despite the placement of multiple chest tubes. A 
massive hemothorax emerged and the patient was disconnected from the ventilator 
during 3 days, remaining on ECMO, in a conservative attempt to solve the 
hemopneumothorax, but without success. A surgery (access by right lateral 
thoracotomy) was tried for closure of the fistula and clots removal, but during the 
procedure tissues were very friable and marked blood loss was seen, forcing massive 
blood transfusion. After the surgery the patient was readmitted in the ICU very 
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unstable, evolving to refractory shock and death a few hours after the end of surgery 
(on the 73rd day of ECMO).   
DISCUSSION 
 In the present report, three AIP cases with refractory severe acute respiratory 
failure rescued with VV-ECMO are described. Extracorporeal gas exchange allowed 
minimization of further ventilator-induced lung injury and the prosecution of a diagnostic 
work-up that included a surgical lung biopsy, bridging the patient to definite treatment 
and eventual recovery. 
All of the patients had no previous lung disease, did not smoke and had an 
acute onset of disease, although with shorter median times for dyspnea development 
than those usually depicted in the literature.3 The evaluation on hospital admission 
highlights severe type 1 respiratory failure with an accompanying inflammatory 
syndrome, without hemodynamic instability or other concomitant major organ 
dysfunction. The chest x-rays showed alterations consistent with pneumonia, and this 
diagnosis was erroneously made, leading to an inadvertent use of antibiotics, without 
any benefits for the patients and delaying the correct diagnosis. The diagnostic work–
up for AIP is very laborious, requiring the exclusion of other diseases and ending with a 
lung biopsy – “idiopathic ARDS”.6 ECMO played a major role as a supportive measure 
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initiated to “buy time” until the final diagnosis was made, the lung inflammatory process 
controlled, the native lung functions re-established and simultaneously avoiding the 
additional lung injury of the aggressive mechanical ventilation needed to support the 
respiratory failure.  
Controversies exist regarding the need and safety of lung biopsy in ICU 
patients, in an era of better laboratory expertise and techniques that can contribute to a 
more accurate diagnosis in the majority of pulmonary diseases. Regarding this 
evidence, lung biopsies are still highlighted in some papers as the only way to perform 
the correct diagnosis in some patients, namely those with persistent ARDS with 
negative blood and BAL results, with potential impact on treatment decisions and on 
outcome.15 The best lung biopsy technic for ICU patients seems to be the surgical one, 
with direct visualization of the lung for better representativeness of the tissue 
specimen. The best timing for its execution, seems to be the early phase of the 
disease, namely the first week of mechanical ventilation, a time where the initiation of 
new treatments can have impact on survival and morbidity.15, 16 The biopsy can be 
safely done at patient bedside, being the pneumothorax, low-grade air leak and 
hemothorax the most frequent complications, with the potential of being life-
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threatening.15 In our case-series a trend to late biopsies was seen, all with associated 
complications, one of them with serious consequences leading to death.  
The best treatment for AIP is still undefined, being steroids and other 
immunomodulatory treatments not free from criticism.5 According to some guidelines, 
early diagnosis and early treatment is highly desirable. Although no controlled data on 
this issue exists, the use of pulsed intravenous methylprednisolone as the first line 
therapy for rapidly progressive interstitial lung diseases is recommended, with the 
possibility of adding a second immunosuppressive agent, such as cyclophosphamide, 
in severe cases.17 As corticosteroids inhibit the production of a number of 
proinflammatory mediators, which are involved in the pathogeneses of AIP and can 
inhibit the fibrotic response, some authors advocate that corticosteroids effectiveness 
depends on the extent and ratio of inflammation to fibrosis at the time of diagnosis.9 
Maybe that is why some papers show lower mortality rates associated with early 
corticosteroids use.9 Reflecting these controversies in this case series, we have used 
three different immunosuppressive regimens.   
Less controversial is the need to support the acute respiratory failure with all the 
specific “weapons” of critical care medicine, namely ECMO, which, when correctly and 
safely performed by experienced teams, can be of great value to some patients. 
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Despite the experience of our ECMO Center, some unfavorable outcomes can still be 
seen, as it was the case of one of our patients, in a very complex situation of persistent 
severe respiratory failure requiring ECMO, shock, multiorgan dysfunction, ECMO 
induced coagulopathy, post operative care of emergent thoracic surgery requiring 
massive blood transfusion and all the other usual complexity typical of this patients, 
that make so challenging our work.  
CONCLUSION 
Our report highlights the potential role of VV-ECMO in the diagnosis and 
management of refractory severe acute respiratory failure associated to AIP. Effective 
extracorporeal gas exchange allows the minimization of further ventilator-induced lung 
injury, the establishment of AIP diagnosis, bridging the patient to diagnosis, definite 
treatment and eventual recovery.  
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Current Knowledge 
Acute Interstitial Pneumonia is a rare form of interstitial lung disease of unknown 
etiology with high mortality rate (>50%). The diagnostic work–up is very laborious, 
requiring the exclusion of other diseases, which ends with a lung biopsy – “idiopathic 
ARDS”. There is no proven effective treatment for AIP. 
What this paper contributes to our knowledge 
With Extracorporeal Membrane Oxygenation, minimization of ventilator-induced lung 
injury is possible. This permits establishment of difficult diagnosis and bridges 
patients to definite treatment and/or recovery. 
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Figure 1 Chest X-ray (A) and Thoracic computed tomography (B) at admission and 
Chest X-ray of the last pulmonology consultation of patient 1. A. consolidation of the 
right and of the inferior two thirds of the left lungs. B. diffuse bilateral ground glass 
pattern and inferior lobar consolidation. C. Complete resolution of bilateral infiltrates.  
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Figure 2 Lung biopsy of patient 1: Diffuse alveolar damage with uniform-appearing 
widning of alveolar septa by fibrosis and pneumocytes hyperplasia (hematoxylin and 
eosin-stained section; x100). 
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Figure 3 Chest X-ray (A) at admission at the Emergency room, Thoracic computed 
tomography (B) pre-ECMO and Chest X-ray of the last rheumatology consultation of 
patient 2. A. heterogeneous infiltrates in both inferior halves of the lungs. B. diffuse 
bilateral ground glass pattern with lobar consolidation and right pneumothorax. C. 
Complete resolution of bilateral infiltrates.  
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Figure 4 Lung biopsy of patient 2: Diffuse alveolar damage with alveolar collapse with 
interstitial fibroblast proliferation (hematoxylin and eosin-stained section; x40). 
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Figure 5 Chest X-ray (A) at Centro Hospitalar São João admission, 1st (B) and 4th (C) 
Thoracic computed tomography and last Chest X-ray of patient 3. A. diffuse bilateral 
infiltration. B. extended areas of consolidation and ground glass pattern more 
exuberant in the in the inferior pulmonary lobes. C. Persistent pneumothorax with 
hemothorax and persistent consolidation. D. diffuse bilateral infiltration 
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Figure 6 Lung biopsy of patient 3: Diffuse alveolar damage with extensive interstitial 
fibroblast proliferation along with alveolar collapse and scant inflammatory cells 
(hematoxylin and eosin-stained section; x100). 
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Table 1 - Characteristics of patients with AIP 
Case  1 2 3 
Gender Female Male Female 
Age 27 59 56 
Comorbidities  Obesity Ulcerative colitis 
Unilateral renal 
agenesis, depressive 
disorder 
Smoking No No No 
Hospital admission:    
Fever Yes Yes Yes 
Resp Rate 32 32 36 
P/F 80 166 56 
Rx Consolidation Consolidation Consolidation 
Initial diagnosis  Severe CAP Severe CAP Severe CAP 
Surgical lung biopsy 
(SLB) 
Yes Yes Yes 
      ICU to SLB (days) 8 14 25 
      ECMO to SLB 
(days) 
2 9 25 
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      Complications  Hemopneumothorax 
Pneumothorax 
Bronchopleural 
fistula 
Hemopneumothorax 
Bronchopleural 
fistula 
Immunosuppression  
Methylprednisolone + 
cyclophosphamide 
Methylprednisolone Methylprednisolone 
Outcome Alive Alive Dead 
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Table 2 - Characteristics of patients requiring ECMO 
Case                                              1 2 3 
Clinical deterioration (days) 
Symptoms to Hospital Admission 10 3 3 
Hospital to ICU admission 0  0 0 
ICU admission to ECMO 6 4 7 
IMV to ECMO 6 3 7 
SAPS II* 26 28 46† 
SOFA Score* 9 10 12 
Before ECMO 
Prone Positioning No Yes Yes 
Neuromuscular blockade Yes  Yes  Yes 
Tidal volume 6 ml/kg (predicted body 
weight)  
Yes Yes Yes 
Plateau pressure < 30 Yes Yes Yes 
Permissive hypercapnia  Yes Yes Yes 
Negative fluid balance  Yes Yes Yes 
Acute circulatory dysfunction No  No  Yes 
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IMV – Invasive Mechanical Ventilation; SAPS II – Simplified Acute Physiology Score II; 
SOFA Score – Sequential Organ Failure Assessment Score; LOS – Length Of Stay; 
*First day of ICU; †24 at 1st UCI 
 
 
Renal replacement therapy No No  No 
Murray Score 3.5 3 3.25 
During ECMO 
Prone Positioning No No No 
Renal replacement therapy No Yes No 
Rest ventilation Yes Yes Yes 
Acute circulatory dysfunction No  No  Yes 
Renal replacement therapy No Yes No 
Mechanical Ventilation (days) 26 35 73 
ECMO (days) 15 15 73 
ICU LOS (days) 28 37 73 
ICU survival Survivor Survivor Non-Survivor 
Hospital Survival Survivor Survivor Non-Survivor 
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Table 3- ECMO characteristics 
Case                                             1 2 3 
Cannulas RIJV - 17 Fr 
RFV - 23 Fr 
RIJV - 19 Fr 
RFV - 25 Fr 
RIJV - 19 Fr 
RFV - 25 Fr 
ECMO Circuit  Rotaflow 
Maquet 
Cardiohelp 
Maquet 
Cardiohelp 
 Maquet 
Total number of oxygenators  1 2 3 
Decannulation complications None None Not applicable  
RIJV - Right Internal Jugular Vein; RFV - Right Femoral Vein; Fr - French 
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Table 4 - Diagnostic work-up 
All the patients had the following diagnostic work-up with negative our normal results 
 Nasal swab for influenza and MRSA, blood cultures, sputum cultures, legionella and 
pneumococcal urinary antigen test, urine culture 
 Serology’s for CMV, EBV, herpes simplex 1 and 2, mycoplasma pneumonia, parvovirus 
B19, HIV, Hepatitis B and C 
 Polymerase chain reaction (PCR) in blood for EBV, CMV, Influenza A e B, Herpes, 
Mycoplasma e Parvovirus B19 
 BAL bacteriological, pneumocystis (immunofluorescence), tuberculosis, mycological, 
virological (sincicial respiratory virus, adenovirus, influenza A e B, parainfluenza 1, 2 and 
3; CMV e Herpes Simplex). 
 PCR in BAL for legionella, mycoplasma, chlamydia, coxiela, influenza A e B, CMV, 
Aspergilus 
 Immunophenotyping of BAL with predominance of neutrophils or lymphocytes 
 Normal determination of immunoglobulin’s, complement, antinuclear antibodies, 
antibodies double stranded DNA, anti neutrophil antibodies, anti glomerular basement 
membrane antibodies 
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 PCR Influenza, Herpes Simplex, Clamydia, Micobacterium Tb, Mycoplasma, CMV, 
pneumocystis, legionella in lung biopsy 
 Bacteriological and mycological studies in lung biopsy and pleural fluid  
 Neoplastic cells, granulomatous lesions, vasculitis, CMV, Herpes simplex, study’s by 
histochemical methods PAS, PAS-E, Grocott and Gram, in lung tissue  
 Normal Brain Natriuretic Peptide  
 Preserved left ventricular systolic function on transthoracic echocardiography 
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References must be listed and numbered in the sequence in which they are first cited in the text. 
Citations must conform to Journal style; see examples below. Authors are responsible for 
accuracy of their references. 
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http://endnote.com/downloads/style/respiratory-care 
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Chang SY, Dabbagh O, Gajic O, Patrawalla A, Elie MC, Talmor DS, et al; on behalf of the 
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Editorial: 
Rouby JJ, Arbelot C, Brisson H, Lu Q, Bouhemad B. Measurement of alveolar recruitment at the 
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2013;58(3):539-542. 
 
Editorial, no author given: 
Asthma: not just for kids (editorial). Johns Hopkins Med Lett Health After 50 2012;24(8):6. 
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during spirometry testing (letter). Respir Care 2013;58(2):e14-e15. author response: e15. 
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content: 
 
Wilkins RL, Stoller JK, Kacmarek RM. Egan’s fundamentals of respiratory care, 9th edition. St 
Louis: Mosby|Elsevier; 2009:400-404, 917. 
 
Corporate authors: 
Panel on Understanding Cross-National Health Differences Among High-Income Countries; 
Committee on Population Division of Behavioral and Social Sciences and Education; Board on 
Population Health and Public Health Practice; National Research Council; Institute of Medicine 
of the National Academies. U.S. health in international perspective: shorter lives, poorer health. 
Washington, DC: National Academies Press; 2013. 
 
Chapter: 
Heffner JE. Chronic obstructive pulmonary disease. In: Hess DR, MacIntyre NR, Mishoe SC, 
Galvin WF, Adams AB. Respiratory care principles and practice, 2nd edition. Sudbury, MA: 
Jones & Bartlett; 2012:735-764. 
 
Online Material 
Static material must be listed in the References and include the digital object identifier (DOI). 
Use a DOI for content published online only. Because these items are static, there is no need to 
include an access date:  
 
Ng S, King CS, Hang J, Clifford R, Lesho EP, Kuschner RA, et al. Severe cavitary pneumonia 
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Research not yet accepted for publication should be cited in the text as personal communication. 
You must obtain written permission from the authors to cite unpublished data.  
 
“Recently, Smith et al found this treatment effective in 45 of 83 patients (Smith R, personal 
communication, 2015).”  
 
Your own unpublished work that has not been accepted for publication should be mentioned in 
the text: “We found this type of aerosol is no more effective than placebo (unpublished data).”  
Quick Look 
The Quick Look boxes in RESPIRATORY CARE provide readers with the concise take-home 
message of the study. Only Original Research articles have Quick Look boxes. Quick Look 
boxes have 2 headings, the first is Current Knowledge and the second is What This Paper 
Contributes To Our Knowledge. 
 
Include your Quick Look text at the end of your main manuscript text file (after the References 
and any Figure Legends) under the heading Quick Look. Double-space all text. 
 
Current Knowledge 
 
Write 2–4 declarative sentences summarizing current understanding of the topic being studied. 
Think of it as defining the state of the art or establishing equipoise. 
 
DO – State the current evidence on the subject 
DO – Provide clear declarative statements 
 
DO NOT – Ask a question 
DO NOT – State what is not known or that a topic “requires further study” or “remains to be 
elucidated” 
 
What This Paper Contributes To Our Knowledge 
 
Write 2–4 declarative sentences summarizing the take-home message of the study. Use past 
tense. Provide only information supported by the data. Do not overstate the importance of your 
results and do not suggest further research; this section is about the paper at hand. 
 
DO – Describe the main take-home points and findings 
DO – Describe the environment (eg, if a lung model was used) 
DO – Write statements that can be understood without re-stating the data 
 
DO NOT – Allude to further work that needs to be accomplished 
DO NOT – Overstate the importance of the findings or speculate. (eg, The use of APRV 
improved oxygenation [data from the study]. Due to improved oxygenation, APRV might reduce 
mortality in ARDS [speculation]). 
DO NOT – Include statistics or numerical data 
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The Editors reserve the right to edit Quick Look boxes for accuracy, style, and length. 
 
 
Example Quick Look  
 
Current knowledge 
The endotracheal tube cuff allows positive pressure ventilation and protects the airway from 
aspiration. Standard cuff pressures of 20–30 cm H2O are typically used to prevent leakage of 
fluid around the cuff and to prevent mucosal injury. In recent years, laboratory evaluations of 
cuffs in glass models have demonstrated reduced fluid leakage, but clinical studies have not 
confirmed these findings in vitro. 
 
What this paper contributes to our knowledge 
In a realistic viscoelastic model of the trachea, endotracheal tube cuffs of different designs 
provided an adequate seal at a pressure of 12 cm H2O. With increased PEEP, higher cuff 
pressures were required. Tubes with a subglottic suction channel performed best in the lateral 
position. 
Figures 
Use of Figures is encouraged. Include only Figures that clarify and augment the text. All Figures 
must be called-out in the text. Number consecutively as Figure 1, Figure 2, etc. 
The first Figure in the report of a clinical trial must be a flow diagram showing phases of the trial 
(ie, enrollment, subject allocation, follow-up, and analysis). See CONSORT. 
Each Figure must be uploaded to Manuscript Central as a separate image file, NOT embedded in 
the text.  
Minimum 1200 dpi required for line art (graphs or drawings), 600 dpi required for images with 
labeling, and 300 required dpi for images (color or black and white) without labeling. 
Radiographs must clearly identify the relevant details and contain no patient identifiers. 
Any identifiable image must be accompanied with written consent (see Ethics of Investigation). 
Identify stains and magnifications for all photomicrographs. 
Arrows, numbers, letters, lines and other markers used to identify parts of a Figure must be 
defined in the Figure Legend. 
Figures are redrawn for stylistic consistency. Contact the Editorial Office if you would like 
assistance in creating an original Figure. 
Figure Legends 
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Every Figure must have a legend explaining every component of the Figure. The legend should 
be self-sufficient and allow the reader to understand the figure without referring to the text.  
Legends are placed at the very end of the manuscript text file. Do not include legends in the 
Figure image files.  
Tables 
Each Table must be uploaded to Manuscript Central as a separate Microsoft Word file, NOT 
embedded in the text. Tables must have a title. The title should be self-sufficient and allow 
readers to understand the Table without referring to the text.  
Tables should be numbered and cited consecutively in the text, Table 1, Table 2, etc. Any 
abbreviations and symbols must be explained in footnotes at the bottom of the Table. For 
footnotes use the following symbols, superscripted, in the following order: *, †, ‡, §, ||, ¶, **, ††. 
Borrowed Figures and Tables 
To include previously published Figures and Tables, you must obtain permission from the 
original copyright holder. Provide the reference citation in the Table footer so that appropriate 
credit can be acknowledged in accordance with copyright law.  
 
Copyright is most often held by the publisher of the journal or book in which the Figure or Table 
originally appeared. It is the author’s responsibility to secure permission. Payment of any fees 
required for borrowed material is the responsibility of the author.  
 
Upload permissions documentation with your manuscript files. 
Acknowledgements 
Names of persons not eligible for authorship, and their contribution and institutional affiliation, 
should be listed in the Acknowledgments. You must obtain written permission from all 
individuals named in the Acknowledgments because inclusion can be taken as the individuals’ 
approval of the paper’s contents.  
Equations 
Write equations as normal text. Do not use the equation function in Microsoft Word or other 
mathematics software. 
Statistical Analysis 
For original research papers, the Editor recommends working with a biostatistician to assure 
appropriate analysis. The Editor may request a letter from your biostatistician assuring that the 
analysis is correct. 
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In the Methods section, identify the statistical tests used to analyze the data. Indicate the P-value 
that was taken to indicate significance. State whether tests were one-tailed or two-tailed; justify 
the use of one-tailed tests. Identify post-hoc analyses. Cite references to support your choice of 
tests and identify any statistical analysis software used. Indicate how the power analysis was 
conducted to determine appropriate sample size. 
Report measurements with an appropriate degree of precision. Report both numerators and 
denominators for percentages. 
For continuous data, description statistics should be expressed as mean and standard deviation 
(not standard error). For ordinal data, median and interquartile range should be reported.  
For ratios (odds ratio, relative risk, etc.), provide 95% confidence interval.  
Report actual P values rather than thresholds. Example: write “P = .18”, not “P > .05” or “P = 
NS.” Note that P cannot equal 0 or 1.  
P values should be expressed to 2 digits for P ≥ .01. P < .001, rather than P < .0001 or P = 
.00001. If P > .99, P = .999 for example, it should be expressed as P > .99.  
An exception is P values between .07 and .03, which the Journal expresses to 3 digits. This is to 
preserve potential meaning of values near .05. 
Authors are encouraged to enlist the expertise of a local statistician. If questions arise during the 
peer review process regarding the statistical analysis, the Editor may ask for proof of input from 
a statistician when the revised manuscript is submitted.  
Units of Measurement 
Always report the units of measurement according to current scientific usage. Standard units of 
measurement and scientific terms may be abbreviated without explanation (eg, L/min, mm Hg, 
pH, O2). The Journal uses most values in Systeme Internationale (SI) units. For blood gas values, 
we prefer mm Hg to kPa. For airway pressure, we prefer cm H2O rather than millibars.  
Pulmonary Terms and Symbols 
Use the Preferred Pulmonary Terms and Symbols (Appendix 1). Use abbreviations sparingly. Do 
NOT invent new abbreviations for terms with long-held standard abbreviations. Use an 
abbreviation only if the term occurs 4 or more times in the manuscript.  
The following commonly used abbreviations do not need to be defined: ARDS, CI, COPD, 
CPAP, DNA, FDA, FEV1, FIO2, FVC, ICU, PaO2, PaCO2, PO2, PCO2, PEEP, SD, SpO2. We also do 
not define units (eg, mL, cm, µm, µL). 
Drugs and Commercial Products 
Precisely identify all drugs and chemicals, doses, and methods of administration. 
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Use generic names instead of trade (proprietary) names for both drugs and equipment. 
At first mention, trade names may be given parenthetically after generic names, including the 
name and location of the manufacturer. For equipment, provide model numbers if available. 
Subjects versus Patients 
 
Individuals enrolled in research are referred to as subjects, not patients. This applies to both 
retrospective and prospective studies.  
Ventilator Modes 
Use the Preferred Ventilator Mode Nomenclature (Appendix 2).  
Language Editing Services 
Poorly written papers will not be accepted. Particularly for authors whose native language is not 
English, it is strongly recommended to work with someone fluent in English science writing. If 
the quality of the English is not acceptable, the Editor may ask the author to submit evidence of 
help by someone fluent in English science writing when the revised manuscript is submitted.  If 
you need assistance, below are some companies that provide language and copyediting services. 
Use of such a service is at the discretion and cost of the authors, and does not guarantee 
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Appendix 1. Preferred Terms and Symbols 
 
Primary Symbols 
S  Saturation 
C content 
F  Fractional concentration 
T  Temperature 
P  Pressure 
V  Volume 
 
Qualifying symbols are denoted by subscripted character; uppercase for values in the 
lungs and lowercase for values in the blood 
A   Alveolar 
I  Inspired 
B  Barometric 
L  Lung 
D  Dead space 
T  Tidal 
E  Expired 
E  Mixed expired 
a  Arterial 
b  Blood 
c  Capillary 
v  Venous 
c′ Pulmonary end-capillary 
v  Mixed venous 
t Time 
 
Pulmonary Function testing 
D/VA  
DLCOsb  Lung diffusing capacity determined by the single-breath technique 
ERV Expiratory reserve volume 
FEF25-75% Forced expiratory flow over the middle half of the FVC 
FEV1 Forced expiratory volume in the first second 
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FEVt Forced expiratory volume in the first t seconds 
FRC Functional residual capacity 
FVC Forced vital capacity 
IC Inspiratory capacity 
IRV  Inspiratory reserve volume 
IVC Inspiratory vital capacity 
MVV Maximal voluntary ventilation 
PEF Peak expiratory flow 
RV  Residual volume 
RV/TLC% Residual volume expressed as percent of TLC 
TGV  thoracic gas volume 
TLC  Total lung capacity 
VA Alveolar gas volume 
VC Vital capacity 
 
Ventilation 
f Breathing frequency 
VT Tidal volume 
VA  Alveolar ventilation 
VD  Dead space ventilation 
VCO2  Carbon dioxide production 
VO2  Oxygen consumption 
V/Q  ventilation-perfusion ratio 
 
Pulmonary mechanics 
C Compliance 
E Elastance 
Gaw Airway conductance 
P0.1 Airway occlusion pressure at 0.1 s 
PA Alveolar pressure 
Paw Pressure in the airway 
Paw  Mean pressure 
PEmax Maximal expiratory pressure 
Pes Esophageal pressure 
PImax Maximal inspiratory pressure 
PIP Peak inspiratory pressure 
PL Transpulmonary pressure 
Ppl Intrapleural pressure 
Pplat Plateau pressure 
R Resistance 
Raw Airway resistance 
RE Expiratory resistance 
RI Inspiratory resistance 
sGaw Specific airway conductance 
WOB Work of breathing 
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Blood gases 
P  Mean pressure 
PO2  Partial pressure of oxygen 
PaO2  Arterial partial pressure of oxygen 
PAO2  Alveolar partial pressure of oxygen 
PaCO2  Arterial partial pressure of carbon dioxide 
PACO2  Alveolar partial pressure of carbon dioxide 
PETCO2  End-tidal partial pressure of carbon dioxide 
PECO2  Mixed exhaled partial pressure of carbon dioxide 
PvCO2  Mixed venous partial pressure of oxygen 
PtcO2  tcPO2 transcutaneous partial pressure of oxygen 
PtcCO2  tcPO2 transcutaneous partial pressure of carbon dioxide 
P(A-a)O2 Alveolar-arterial PO2 difference 
P(a/A)O2 Arterial to alveolar PO2 ratio 
CaO2  Arterial oxygen content 
CvCO2  Mixed venous oxygen content 
Cc'O2  Pulmonary capillary oxygen content 
SaO2  Arterial oxygen saturation 
SpO2  Oxygen saturation as measured by pulse oximetry 
SvCO2  Mixed venous oxygen saturation 
C(a - v)O2  Arterial-venous oxygen content difference 
pH  
Q  Blood flow  
QT  Cardiac output 
Q  Blood volume 
QS/QT  Shunt fraction 
R Respiratory quotient 
 
Ventilator Nomenclature 
APRV Airway pressure release ventilation 
AVAPS Average volume assured pressure support 
CMV Continuous mandatory ventilation (rather than assist-control) 
CPAP Continuous positive airway pressure 
EPAP Expiratory positive airway pressure 
FIO2  Fraction of inspired oxygen (expressed as a fraction, not percent) 
HFJV High frequency jet ventilation 
HFOV High frequency oscillatory ventilation 
I:E Inspiratory time to expiratory time ratio 
IPAP Inspiratory positive airway pressure 
NAVA Neurally adjusted ventilatory assist 
NIV Noninvasive ventilation (rather than NPPV) 
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PAV Proportional assist ventilation 
PC-CMV Pressure-control continuous mandatory ventilation (rather than pressure assist-
control) 
PC-IMV Pressure-control intermittent mandatory ventilation 
PCIRV Pressure control inverse ration ventilation 
PEEP Positive end-expiratory pressure 
PRVC Pressure regulated volume control 
PSV Pressure support ventilation 
TE Expiratory time 
TI Inspiratory time 
VC-CMV Volume-control continuous mandatory ventilation (preferred rather than volume 
assist-control) 
VC-IMV Volume-control intermittent mandatory ventilation 
VDR  Volumetric diffusion respiration 
VS Volume support 
 
Other preferred terms 
6MWD
 
Six-minute walk distance 
6MWT
 
Six-minute walk test 
AARC  American Association for Respiratory Care 
ABG  Arterial blood gas 
ALS  Amyotrophic lateral sclerosis 
ARDS Acute respiratory distress syndrome 
ARF  Acute respiratory failure 
ATPS Ambient temperature and pressure saturated 
BMI Body mass index 
BPAP Bilevel positive airway pressure (rather than BiPAP) 
BTPS Body temperature and pressure saturated 
CCI Chronic critical illness 
CDC Centers for Disease and Prevention 
CF Cystic fibrosis 
CI Confidence interval 
CMS Centers for Medicare and Medicaid services 
CO  Carbon monoxide 
COPD Chronic obstructive pulmonary disease 
CPR  Cardiopulmonary resuscitation 
CPT 
 
Chest physical therapy 
CT Computed tomography 
DNR Do not resuscitate 
DPI  Dry powder inhaler 
EAdi Electrical activity of the diaphragm 
EBUS Endobronchial ultrasound 
ECLS Extracorporeal life support 
ECMO  Extracorporeal membrane oxygenation 
EIB  Exercise-induced bronchospasm 
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FDA  US Food and Drug Administration 
HFNC High flow nasal cannula 
HME Heat and moisture exchanger 
HMEF  Heat and moisture exchanging filter 
HRCT High resolution computed tomography 
Hz Hertz 
IBW Ideal body weight 
IBW Ideal body weight 
ICP  Intracranial pressure 
ICU Intensive care unit 
ICU  Intensive care unit 
ILD  Interstitial lung disease 
IQR Interquartile range 
MDI Metered dose inhaler 
MRI  Magnetic resonance imaging 
NG  Nasogastric (tube) 
NIH  National Institutes of Health 
NO Nitric oxide 
OSA  Obstructive sleep apnea 
PAP Positive airway pressure 
PEP Positive expiratory pressure 
PFT  Pulmonary function test or testing 
PMV Prolonged mechanical ventilation 
PSG Polysomnography 
r Correlation coefficient 
RSBI Rapid shallow breathing index 
RT Respiratory therapist 
SBT Spontaneous breathing trial 
SD Standard deviation 
SE Standard error 
STPD Standard temperature and pressure dry 
TBLB Transbronchial lung biopsy 
TBNA Transbronchial needle aspiration 
VA  Veterans Administration 
VAE Ventilator-associated event 
VAC Ventilator-associated condition 
VAP Ventilator-associated pneumonia 
VILI Ventilator induced lung injury 
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Appendix 2. Preferred Ventilator Mode Nomenclature 
 
Preferred 
Term 
Preferred 
Symbol Intended Meaning Similar Terms to be Avoided 
Volume 
Control 
Continuous 
Mandatory 
Ventilation 
VC-CMV Mechanical 
ventilation with 
preset tidal volume 
and inspiratory flow. 
Every breath is 
mandatory (ie, 
inspiration is patient 
or machine trigged 
and machine cycled). 
Assist/Control, A/C, CMV, 
Volume Assist/Control, Volume 
Control, Volume Limited 
Ventilation, Volume Control 
Ventilation, Controlled 
Ventilation, Volume Targeted 
Ventilation 
Volume 
Control 
Intermittent 
Mandatory 
Ventilation 
VC-IMV Mechanical 
ventilation with 
preset tidal volume 
and inspiratory flow. 
Spontaneous breaths 
(ie, inspiration is 
patient triggered and 
patient cycled) can 
exist between 
mandatory breaths. 
Synchronized Intermittent 
Mandatory Ventilation, SIMV 
Pressure 
Control 
Continuous 
Mandatory 
Ventilation 
PC-CMV Mechanical 
ventilation with 
preset inspiratory 
pressure and 
inspiratory time. 
Every breath is 
mandatory (ie, patient 
or machine trigged 
and machine cycled). 
Assist/Control, A/C, CMV, 
Pressure Assist/Control, 
Pressure Control, Pressure 
Limited Ventilation, Pressure 
Control Ventilation, Pressure 
Targeted Ventilation 
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Pressure 
Control 
Intermittent 
Mandatory 
Ventilation 
PC-IMV Mechanical 
ventilation with 
preset inspiratory 
pressure and 
inspiratory time. 
Spontaneous breaths 
(ie, inspiration is 
patient triggered and 
patient cycled) can 
exist between 
mandatory breaths. 
Synchronized Intermittent 
Mandatory Ventilation, SIMV 
Continuous 
Spontaneous 
Ventilation 
CSV Any mode of 
mechanical 
ventilation where 
every breath is 
spontaneous (ie, 
patient triggered and 
patient cycled) 
Spont 
Mandatory 
Breath 
None A breath type during 
mechanical 
ventilation for which 
inspiration is machine 
triggered and/or 
machine cycled. 
Machine breath, mechanical 
breath 
Spontaneous 
Breath 
None A breath type for 
which inspiration is 
both patient-triggered 
and patient cycled. 
Applies to assisted or 
unassisted breathing. 
N/A 
Assisted 
Ventilation or 
Breath 
None Ventilation or breath 
for which a machine 
provides some or all 
of the work of 
breathing. 
Patient triggered ventilation or 
breath 
24 
 
	   	   	  
Patient 
Triggered 
Breath 
None A breath that is 
initiated by the 
patient, independent 
of ventilator settings 
for frequency. 
Patient assisted breath, assisted 
breath 
Auto-
triggering 
None Unintended initiation 
of breath delivery by 
the ventilator, eg, by 
an external 
disturbance such as 
movement of the 
breathing tube or an 
inappropriate trigger 
sensitivity setting. 
Auto-cycling 
 
 
 
  
 
 
